Specify a stock or a cryptocurrency in the search bar to get a summary
Celldex Therapeutics Inc
CLDXCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Address: Perryville III Building, Hampton, NJ, United States, 08827
Analytics
WallStreet Target Price
67.1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CLDX
Dividend Analytics CLDX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CLDX
Stock Valuation CLDX
Financials CLDX
Results | 2019 | Dynamics |